Antiobesity and antidiabetic effects of brain-derived neurotrophic factor in rodent models of leptin resistance

T. Nakagawa, Yoshihiro Ogawa, K. Ebihara, M. Yamanaka, A. Tsuchida, M. Taiji, H. Noguchi, K. Nakao

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

OBJECTIVE: Obesity in rodents and humans is mostly associated with elevated plasma leptin concentrations, suggesting a new pathological concept of 'leptin resistance'. We have demonstrated that brain-derived neurotrophic factor (BDNF) can improve obesity and diabetes of C57BL/KsJ db/db (db/db) mice. In this study, we investigated whether or not BDNF is effective in two different models of leptin resistance, an acquired model and a genetic model. DESIGN: C57BL/6J mice rendered obese by consumption of a high-fat diet (diet-induced obesity (DIO) mice) were used as an acquired model and lethal yellow ogouti mice (KKAy mice) as a genetic model of leptin resistance. Food intake and glucose metabolism were studied after acute or repetitive administration of BDNF. RESULTS: Intraperitoneal administration of BDNF (10 mg/kg, twice/day) significantly reduced cumulative food intake of DIO and KKAy mice, whereas they were unresponsive to leptin administration. Repetitive subcutaneous administration of BDNF (10 mg/kg daily for 6 days) reduced food intake and improved impaired glucose tolerance in DIO mice. Pair feeding of vehicle-treated DIO mice with the same amount of chow consumed by the BDNF-treated group did not improve the impaired glucose homeostasis, indicating that the antidiabetic effect is not due to decreased food intake. We also observed that BDNF is effective in improving obesity and diabetes of KKAy mice. CONCLUSION: This study demonstrated antiobesity and antidiabetic effects of BDNF in two different models of leptin resistance, thereby suggesting the therapeutic potential of BDNF in the treatment of leptin-resistant obesity and diabetes.

Original languageEnglish
Pages (from-to)557-565
Number of pages9
JournalInternational Journal of Obesity
Volume27
Issue number5
DOIs
Publication statusPublished - May 1 2003

Fingerprint

Brain-Derived Neurotrophic Factor
Leptin
Hypoglycemic Agents
Rodentia
Obesity
Eating
Diet
Genetic Models
Glucose
Glucose Intolerance
High Fat Diet
Inbred C57BL Mouse
Homeostasis

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics

Cite this

Antiobesity and antidiabetic effects of brain-derived neurotrophic factor in rodent models of leptin resistance. / Nakagawa, T.; Ogawa, Yoshihiro; Ebihara, K.; Yamanaka, M.; Tsuchida, A.; Taiji, M.; Noguchi, H.; Nakao, K.

In: International Journal of Obesity, Vol. 27, No. 5, 01.05.2003, p. 557-565.

Research output: Contribution to journalArticle

Nakagawa, T. ; Ogawa, Yoshihiro ; Ebihara, K. ; Yamanaka, M. ; Tsuchida, A. ; Taiji, M. ; Noguchi, H. ; Nakao, K. / Antiobesity and antidiabetic effects of brain-derived neurotrophic factor in rodent models of leptin resistance. In: International Journal of Obesity. 2003 ; Vol. 27, No. 5. pp. 557-565.
@article{ec8fb679fcfb4ca9baa1d7a1bd4fb9de,
title = "Antiobesity and antidiabetic effects of brain-derived neurotrophic factor in rodent models of leptin resistance",
abstract = "OBJECTIVE: Obesity in rodents and humans is mostly associated with elevated plasma leptin concentrations, suggesting a new pathological concept of 'leptin resistance'. We have demonstrated that brain-derived neurotrophic factor (BDNF) can improve obesity and diabetes of C57BL/KsJ db/db (db/db) mice. In this study, we investigated whether or not BDNF is effective in two different models of leptin resistance, an acquired model and a genetic model. DESIGN: C57BL/6J mice rendered obese by consumption of a high-fat diet (diet-induced obesity (DIO) mice) were used as an acquired model and lethal yellow ogouti mice (KKAy mice) as a genetic model of leptin resistance. Food intake and glucose metabolism were studied after acute or repetitive administration of BDNF. RESULTS: Intraperitoneal administration of BDNF (10 mg/kg, twice/day) significantly reduced cumulative food intake of DIO and KKAy mice, whereas they were unresponsive to leptin administration. Repetitive subcutaneous administration of BDNF (10 mg/kg daily for 6 days) reduced food intake and improved impaired glucose tolerance in DIO mice. Pair feeding of vehicle-treated DIO mice with the same amount of chow consumed by the BDNF-treated group did not improve the impaired glucose homeostasis, indicating that the antidiabetic effect is not due to decreased food intake. We also observed that BDNF is effective in improving obesity and diabetes of KKAy mice. CONCLUSION: This study demonstrated antiobesity and antidiabetic effects of BDNF in two different models of leptin resistance, thereby suggesting the therapeutic potential of BDNF in the treatment of leptin-resistant obesity and diabetes.",
author = "T. Nakagawa and Yoshihiro Ogawa and K. Ebihara and M. Yamanaka and A. Tsuchida and M. Taiji and H. Noguchi and K. Nakao",
year = "2003",
month = "5",
day = "1",
doi = "10.1038/sj.ijo.0802265",
language = "English",
volume = "27",
pages = "557--565",
journal = "International Journal of Obesity",
issn = "0307-0565",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Antiobesity and antidiabetic effects of brain-derived neurotrophic factor in rodent models of leptin resistance

AU - Nakagawa, T.

AU - Ogawa, Yoshihiro

AU - Ebihara, K.

AU - Yamanaka, M.

AU - Tsuchida, A.

AU - Taiji, M.

AU - Noguchi, H.

AU - Nakao, K.

PY - 2003/5/1

Y1 - 2003/5/1

N2 - OBJECTIVE: Obesity in rodents and humans is mostly associated with elevated plasma leptin concentrations, suggesting a new pathological concept of 'leptin resistance'. We have demonstrated that brain-derived neurotrophic factor (BDNF) can improve obesity and diabetes of C57BL/KsJ db/db (db/db) mice. In this study, we investigated whether or not BDNF is effective in two different models of leptin resistance, an acquired model and a genetic model. DESIGN: C57BL/6J mice rendered obese by consumption of a high-fat diet (diet-induced obesity (DIO) mice) were used as an acquired model and lethal yellow ogouti mice (KKAy mice) as a genetic model of leptin resistance. Food intake and glucose metabolism were studied after acute or repetitive administration of BDNF. RESULTS: Intraperitoneal administration of BDNF (10 mg/kg, twice/day) significantly reduced cumulative food intake of DIO and KKAy mice, whereas they were unresponsive to leptin administration. Repetitive subcutaneous administration of BDNF (10 mg/kg daily for 6 days) reduced food intake and improved impaired glucose tolerance in DIO mice. Pair feeding of vehicle-treated DIO mice with the same amount of chow consumed by the BDNF-treated group did not improve the impaired glucose homeostasis, indicating that the antidiabetic effect is not due to decreased food intake. We also observed that BDNF is effective in improving obesity and diabetes of KKAy mice. CONCLUSION: This study demonstrated antiobesity and antidiabetic effects of BDNF in two different models of leptin resistance, thereby suggesting the therapeutic potential of BDNF in the treatment of leptin-resistant obesity and diabetes.

AB - OBJECTIVE: Obesity in rodents and humans is mostly associated with elevated plasma leptin concentrations, suggesting a new pathological concept of 'leptin resistance'. We have demonstrated that brain-derived neurotrophic factor (BDNF) can improve obesity and diabetes of C57BL/KsJ db/db (db/db) mice. In this study, we investigated whether or not BDNF is effective in two different models of leptin resistance, an acquired model and a genetic model. DESIGN: C57BL/6J mice rendered obese by consumption of a high-fat diet (diet-induced obesity (DIO) mice) were used as an acquired model and lethal yellow ogouti mice (KKAy mice) as a genetic model of leptin resistance. Food intake and glucose metabolism were studied after acute or repetitive administration of BDNF. RESULTS: Intraperitoneal administration of BDNF (10 mg/kg, twice/day) significantly reduced cumulative food intake of DIO and KKAy mice, whereas they were unresponsive to leptin administration. Repetitive subcutaneous administration of BDNF (10 mg/kg daily for 6 days) reduced food intake and improved impaired glucose tolerance in DIO mice. Pair feeding of vehicle-treated DIO mice with the same amount of chow consumed by the BDNF-treated group did not improve the impaired glucose homeostasis, indicating that the antidiabetic effect is not due to decreased food intake. We also observed that BDNF is effective in improving obesity and diabetes of KKAy mice. CONCLUSION: This study demonstrated antiobesity and antidiabetic effects of BDNF in two different models of leptin resistance, thereby suggesting the therapeutic potential of BDNF in the treatment of leptin-resistant obesity and diabetes.

UR - http://www.scopus.com/inward/record.url?scp=0038028204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038028204&partnerID=8YFLogxK

U2 - 10.1038/sj.ijo.0802265

DO - 10.1038/sj.ijo.0802265

M3 - Article

C2 - 12704399

AN - SCOPUS:0038028204

VL - 27

SP - 557

EP - 565

JO - International Journal of Obesity

JF - International Journal of Obesity

SN - 0307-0565

IS - 5

ER -